Event details from: Seminar by: Henriette O’Geen

Date
2 October 2024
Time
14:00 – 15:00
Room
L0.06

Epigenetic editing is emerging as a safe way to treat genetic disorders. Indeed, great advances have been made recently to achieve long-term repression of target gene expression by engineering de novo DNA methylation. However, before epigenetic editors can be translated into clinical settings, we need to have a deeper understanding of longevity of unintended off-target events, how widespread off-target methylation really is, and if some loci have a propensity to retain ectopic methylation. We use “hit-and-run” epigenome editing to identify chromatin features that predispose genomic regions to not only gain, but also retain off-target methylation. While the predominant effect of promoter methylation is gene repression, we identify a distinct subset of promoters where hyper methylation often leads to paradoxical gene activation. We identify a novel mechanism of how DNA methylation can contribute to gene activation, with broader implications for cancer and development.